Phaseline

Companies › Biopharma Plasma

Biopharma Plasma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Immunology; next expected readout Apr 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BP-SCIG 20%
Human normal immunoglobulin G (IgG) replacement therapy
–Phase 3Primary Immunodeficiency DiseasesApr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07346859BP-SCIG 20%Phase 3Primary Immunodeficiency DiseasesImmunologyApr 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Psoriasis Research Institute of Guangzhou KalVista Pharmaceuticals Triple Hair Infant Bacterial Therapeutics Aresus Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.